The haploinsufficiency of this enzyme determines an increase in insulin-like growth factor binding protein 2 (IGFBP2) expression and the subsequent activation of the insulin-like growth factor receptor (IGF-R) signaling, which cause resistance to BRAF and MEK inhibition in BRAF-mutant melanoma models [117]. The gene discussed is MAP2K7; the disease is melanoma.